TransCode Therapeutics (RNAZ) Short Interest Ratio & Short Volume $7.61 +0.05 (+0.66%) As of 11:10 AM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TransCode Therapeutics Short Interest DataTransCode Therapeutics (RNAZ) has a short interest of 115,400 shares, representing 13.89% of the float (the number of shares available for trading by the public). This marks a -0.77% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 101,905 shares to cover all short positions.Current Short Interest115,400 sharesPrevious Short Interest116,300 sharesChange Vs. Previous Month-0.77%Dollar Volume Sold Short$765.10 thousandShort Interest Ratio0.4 Days to CoverLast Record DateMay 31, 2025Outstanding Shares833,000 sharesFloat Size831,100 sharesShort Percent of Float13.89%Today's Trading Volume14,128 sharesAverage Trading Volume101,905 sharesToday's Volume Vs. Average14% Short Selling TransCode Therapeutics? Sign up to receive the latest short interest report for TransCode Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRNAZ Short Interest Over TimeRNAZ Days to Cover Over TimeRNAZ Percentage of Float Shorted Over Time TransCode Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/2025115,400 shares $765.10 thousand -0.8%13.9%0.4 $6.63 5/15/2025116,300 shares $889.70 thousand -89.8%14.0%0.4 $7.65 4/30/20251,140,000 shares $12.98 million +9.6%5.4%0.1 $11.38 4/15/20251,040,000 shares $413.92 thousand -59.2%5.0%0.1 $0.40 3/31/20252,550,000 shares $1.26 million +650.4%12.2%0.4 $0.50 3/15/2025339,800 shares $264.30 thousand -37.2%54.3%0.1 $0.78 2/28/2025540,900 shares $1.07 million +232.0%81.8%0.3 $1.98 2/15/2025162,900 shares $1.69 million -55.8%24.7%0.1 $10.36 1/31/2025368,300 shares $2.78 million +355.3%55.7%0.2 $7.56 1/15/202580,900 shares $258.07 thousand -9.7%11.6%0.2 $3.19 Get the Latest News and Ratings for RNAZ and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202489,600 shares $301.95 thousand +71.0%12.9%1.5 $3.37 12/15/202452,400 shares $388.81 thousand +184.8%7.5%0.9 $7.42 11/30/202418,400 shares $6.97 million -91.5%2.7%0.4 $378.97 11/15/2024215,500 shares $73.21 thousand -71.0%1.3%0.1 $0.34 10/31/2024743,600 shares $345.77 thousand -39.1%4.3%0.4 $0.47 10/15/20241,220,000 shares $901.58 thousand -11.6%7.1%0.6 $0.74 9/30/20241,380,000 shares $787.98 thousand +52.5%8.0%0.7 $0.57 9/15/2024904,700 shares $234.41 thousand +224.7%5.3%0.6 $0.26 8/31/2024278,600 shares $73.38 thousand +58.5%1.6%0.2 $0.26 8/15/2024175,800 shares $43.95 thousand -89.3%1.0%0.2 $0.25 7/31/20241,640,000 shares $459.20 thousand +6,539.7%9.6%1.1 $0.28 7/15/202424,700 shares $22.24 thousand -85.2%0.4%0 $0.90 6/30/2024167,200 shares $168.04 thousand -62.7%2.5%0.1 $1.01 6/15/2024448,500 shares $538.20 thousand -56.0%6.9%0.4 $1.20 5/31/20241,020,000 shares $1.81 million +486.5%15.6%0.8 $1.78 5/15/2024173,900 shares $140.27 thousand +16.2%2.7%0.1 $0.81 4/30/2024149,600 shares $90.82 thousand +704.3%2.3%0.2 $0.61 4/15/202418,600 shares $9.98 thousand -53.5%0.3%0 $0.54 3/31/202440,000 shares $27.32 thousand -77.1%0.6%0.1 $0.68 3/15/2024174,800 shares $120.79 thousand +71.4%2.7%0.3 $0.69 2/29/2024102,000 shares $71.87 thousand -53.8%1.6%0.2 $0.70 2/15/2024220,900 shares $145.79 thousand -70.8%3.4%0.4 $0.66 1/31/2024755,300 shares $521.91 thousand +7,529.3%13.0%1.6 $0.69 1/15/20249,900 shares $49.50 thousand -97.6%1.8%0 $5.00 12/31/2023405,000 shares $66.74 thousand -7.4%N/A0.1 $0.16 12/15/2023437,500 shares $74.16 thousand -31.3%2.0%0.1 $0.17 11/30/2023637,200 shares $156.75 thousand +31.8%3.0%0.1 $0.25 11/15/2023483,300 shares $138.61 thousand -63.4%2.5%0.1 $0.29 10/31/20231,320,000 shares $488.66 thousand +562.0%7.4%0.2 $0.37 10/15/2023199,400 shares $86.10 thousand +173.9%6.2%0 $0.43Gold is soaring. Here’s how to get paid from it (Ad)Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.Click here to discover the income ETF behind it all. 9/30/202372,800 shares $36.60 thousand -42.4%4.5%0 $0.50 9/15/2023126,400 shares $84.51 thousand +418.0%7.1%0.1 $0.67 8/31/202324,400 shares $35.38 thousand +1,255.6%1.7%0.2 $1.45 8/15/20231,800 shares $2.92 thousand -87.8%0.1%0 $1.62 7/31/202314,700 shares $32.34 thousand -85.5%2.5%0.1 $2.20 7/15/2023101,500 shares $257.81 thousand +81.9%16.9%0.4 $2.54 6/30/202355,800 shares $128.34 thousand +14.6%9.3%0.2 $2.30 6/15/202348,700 shares $129.06 thousand +79.7%8.1%0.2 $2.65 5/31/202327,100 shares $113.82 thousand +22.1%4.4%0.2 $4.20 5/15/202322,200 shares $135.11 thousand -96.6%N/A0.5 $6.09 4/30/2023653,200 shares $206.35 thousand +2.7%5.6%0.4 $0.32 4/15/2023636,000 shares $250.97 thousand +99.5%5.5%0.4 $0.39 3/31/2023318,800 shares $107.91 thousand +21.0%2.8%0.2 $0.34 3/15/2023263,500 shares $91.62 thousand -51.3%2.3%0.2 $0.35 2/28/2023541,400 shares $282.07 thousand -42.9%4.7%0.1 $0.52 2/15/2023948,400 shares $635.43 thousand +104.5%7.5%0.2 $0.67 1/31/2023463,700 shares $348.15 thousand +0.8%5.3%0.2 $0.75 1/15/2023459,900 shares $281.46 thousand -43.5%5.3%0.1 $0.61 12/30/2022814,100 shares $547.89 thousand -22.5%9.4%0.3 $0.67 12/15/20221,050,000 shares $472.29 thousand +2,849.4%12.1%0.4 $0.45 11/30/202235,600 shares $14.24 thousand +368.4%0.4%0 $0.40 11/15/20227,600 shares $4.16 thousand -96.5%0.1%0 $0.55 10/31/2022218,800 shares $147.03 thousand +478.8%2.5%0.3 $0.67 10/15/202237,800 shares $42.00 thousand -2.1%0.4%1.9 $1.11 9/30/202238,600 shares $42.46 thousand +565.5%0.4%1.9 $1.10 9/15/20225,800 shares $6.73 thousand -29.3%0.1%0.3 $1.16 8/31/20228,200 shares $9.84 thousand +90.7%0.1%0.2 $1.20 8/15/20224,300 shares $5.55 thousand -66.4%0.1%0.1 $1.29 7/31/202212,800 shares $18.18 thousand +1.6%0.2%0.3 $1.42 7/15/202212,600 shares $16.63 thousand +26.0%0.1%0.3 $1.32 6/30/202210,000 shares $12.60 thousand +1.0%0.1%0.2 $1.26 6/15/20229,900 shares $12.57 thousand -52.9%0.1%0.3 $1.27 5/31/202221,000 shares $38.64 thousand -15.7%0.2%1.1 $1.84 5/15/202224,900 shares $56.03 thousand -46.6%0.3%1.5 $2.25 4/30/202246,600 shares $127.22 thousand +88.7%0.5%2.9 $2.73 4/15/202224,700 shares $70.81 thousand -44.9%0.3%1.4 $2.87 3/31/202244,800 shares $129.02 thousand +37.9%0.5%2 $2.88 3/15/202232,500 shares $70.20 thousand -38.2%0.4%0.9 $2.16 2/28/202252,600 shares $112.04 thousand -37.8%0.7%1.3 $2.13 2/15/202284,600 shares $181.04 thousand -12.6%1.2%1.6 $2.14 1/31/202296,800 shares $222.64 thousand -24.7%1.4%1.6 $2.30 1/15/2022128,500 shares $322.54 thousand +51.4%1.8%1.6 $2.51 12/31/202184,900 shares $215.65 thousand +0.7%1.2%0.7 $2.54 12/15/202184,300 shares $207.38 thousand +157.0%1.2%0.3 $2.46 11/30/202132,800 shares $90.20 thousand +32.8%0.5%0 $2.75 11/15/202124,700 shares $73.61 thousand -86.7%0.4%0 $2.98 10/29/2021185,900 shares $526.10 thousand -22.9%2.6%0 $2.83 10/15/2021241,100 shares $776.34 thousand -47.1%3.4%0.1 $3.22 9/30/2021455,400 shares $1.36 million +1,350.3%6.4%0.1 $2.99 9/15/202131,400 shares $81.01 thousand -39.7%0.4%0 $2.58Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 8/31/202152,100 shares $158.38 thousand +128.5%0.7%0 $3.04 8/13/202122,800 shares $65.44 thousand No Change0.4%0 $2.87 RNAZ Short Interest - Frequently Asked Questions What is TransCode Therapeutics' current short interest? Short interest is the volume of TransCode Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 31st, traders have sold 115,400 shares of RNAZ short. 13.89% of TransCode Therapeutics' shares are currently sold short. Learn More on TransCode Therapeutics' current short interest. What is a good short interest percentage for TransCode Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.89% of TransCode Therapeutics' floating shares are currently sold short. Is TransCode Therapeutics' short interest increasing or decreasing? TransCode Therapeutics saw a decrease in short interest in May. As of May 31st, there was short interest totaling 115,400 shares, a decrease of 0.8% from the previous total of 116,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is TransCode Therapeutics' float size? TransCode Therapeutics currently has issued a total of 833,000 shares. Some of TransCode Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TransCode Therapeutics currently has a public float of 831,100 shares. How does TransCode Therapeutics' short interest compare to its competitors? 13.89% of TransCode Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to TransCode Therapeutics: Cyclo Therapeutics, Inc. (3.55%), Ovid Therapeutics Inc. (2.79%), Imunon, Inc. (33.31%), CytoMed Therapeutics Limited (1.24%), CASI Pharmaceuticals, Inc. (0.47%), Lisata Therapeutics, Inc. (0.42%), Enlivex Therapeutics Ltd. (0.53%), Q32 Bio Inc. (10.35%), MIRA Pharmaceuticals, Inc. (1.88%), Finch Therapeutics Group, Inc. (0.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short TransCode Therapeutics stock? Short selling RNAZ is an investing strategy that aims to generate trading profit from TransCode Therapeutics as its price is falling. RNAZ shares are trading up $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TransCode Therapeutics? A short squeeze for TransCode Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RNAZ, which in turn drives the price of the stock up even further. How often is TransCode Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RNAZ, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Cyclo Therapeutics Short Interest Data Ovid Therapeutics Short Interest Data Imunon Short Interest Data CytoMed Therapeutics Short Interest Data CASI Pharmaceuticals Short Interest Data Lisata Therapeutics Short Interest Data Enlivex Therapeutics Short Interest Data Q32 Bio Short Interest Data MIRA Pharmaceuticals Short Interest Data Finch Therapeutics Group Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RNAZ) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAZ Stock Free RNAZ Stock Alerts